Given the multi-faceted roles of filamin A, targeting its phosphorylation in different disease may offer potential in alleviating disease phenotypes, for instance in metastatic progression of breast and prostate cancers, compared with a traditional pharmacological inhibition approach which may be unfavourable given filamin A's complex scaffolding of orthogonal actin networks as wells as discrete signalosomes vital for compartmentalised responses to different stimuli. The gene discussed is FLNA; the disease is prostate cancer.